Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 26, 2023

Investigational Drug Information for Palifosfamide

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Palifosfamide?

Palifosfamide is an investigational drug.

There have been 8 clinical trials for Palifosfamide. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1^st 2012.

The most common disease conditions in clinical trials are Neoplasms, Lung Neoplasms, and Testicular Neoplasms. The leading clinical trial sponsors are Ziopharm, Indiana University School of Medicine, and [disabled in preview].

Summary for Palifosfamide

US Patents	0
International Patents	0
US Patent Applications	371
WIPO Patent Applications	237
Japanese Patent Applications	99
Clinical Trial Progress	Phase 3 (2012-05-01)
Vendors	46

Recent Clinical Trials for Palifosfamide

Title	Sponsor	Phase
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.	Ziopharm	Phase 2
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors	Ziopharm	Phase 2
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors	Indiana University School of Medicine	Phase 2

See all Palifosfamide clinical trials

Clinical Trial Summary for Palifosfamide

Top disease conditions for Palifosfamide

Top clinical trial sponsors for Palifosfamide

See all Palifosfamide clinical trials

US Patents for Palifosfamide

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Baxter

Mallinckrodt

Boehringer Ingelheim

McKesson

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.